구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | proposed trastuzumab biosimilar (SB3, SB3 (proposed trastuzumab biosimilar)) Roche / Genentech·HER2 1 trials |
|---|---|
Overview Program | SB3 (proposed trastuzumab biosimilar) |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | HER2 |
Overview Indication | Breast Neoplasms |
Overview Phase | PRECLINICAL |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Antimony-resistant plant growth-promoting bacteria and ferrous iron (Fe 2+ ) synergistically alleviate antimony stress in rice by iron plaque and metabolic regulation.. Antimony (Sb) contamination in paddy soils poses a serious risk to rice production and food security. Conventional iron plaque (IP)-based remediation strategies often inadvertently increase Sb uptake in rice plants. In this study, … |
Clinical Safety signal | Antimony-resistant plant growth-promoting bacteria and ferrous iron (Fe 2+ ) synergistically alleviate antimony stress in rice by iron plaque and metabolic regulation.. Antimony (Sb) contamination in paddy soils poses a serious risk to rice production and food security. Conventional iron plaque (IP)-based remediation strategies often inadvertently increase Sb uptake in rice plants. In this study, … |
Clinical Selected reported efficacy | ORR 91.2% |
Clinical Reported ORR | 91.2% |
Clinical Result source | ClinicalTrials.gov NCT02149524 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT02149524 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | proposed trastuzumab biosimilar (SB3, SB3 (proposed trastuzumab biosimilar)) Roche / Genentech·HER2 1 trials |
|---|---|
Overview Program | SB3 (proposed trastuzumab biosimilar) |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | HER2 |
Overview Indication | Breast Neoplasms |
Overview Phase | PRECLINICAL |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Antimony-resistant plant growth-promoting bacteria and ferrous iron (Fe 2+ ) synergistically alleviate antimony stress in rice by iron plaque and metabolic regulation.. Antimony (Sb) contamination in paddy soils poses a serious risk to rice production and food security. Conventional iron plaque (IP)-based remediation strategies often inadvertently increase Sb uptake in rice plants. In this study, … |
Clinical Safety signal | Antimony-resistant plant growth-promoting bacteria and ferrous iron (Fe 2+ ) synergistically alleviate antimony stress in rice by iron plaque and metabolic regulation.. Antimony (Sb) contamination in paddy soils poses a serious risk to rice production and food security. Conventional iron plaque (IP)-based remediation strategies often inadvertently increase Sb uptake in rice plants. In this study, … |
Clinical Selected reported efficacy | ORR 91.2% |
Clinical Reported ORR | 91.2% |
Clinical Result source | ClinicalTrials.gov NCT02149524 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT02149524 |
추천 비교
추천 비교